---
title: "Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291144397.md"
description: "In Boston on June 29, 2026, Elicio Therapeutics, Inc. (Nasdaq: ELTX) revealed that it has been included in the Russell 2000 ® and Russell 3000 ® Indexes. This change came into effect after the U.S. market closed on June 26, 2026, during the annual reconstitution of the 2026 Russell indexes. Elicio is a clinical-stage biotechnology company focused on developing advanced immunotherapies for cancers fueled by KRAS."
datetime: "2026-06-29T12:02:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291144397.md)
  - [en](https://longbridge.com/en/news/291144397.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291144397.md)
generator: "portal-rs"
---

# Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes

In Boston on June 29, 2026, Elicio Therapeutics, Inc. (Nasdaq: ELTX) revealed that it has been included in the Russell 2000 ® and Russell 3000 ® Indexes. This change came into effect after the U.S. market closed on June 26, 2026, during the annual reconstitution of the 2026 Russell indexes. Elicio is a clinical-stage biotechnology company focused on developing advanced immunotherapies for cancers fueled by KRAS.

### Related Stocks

- [ELTX.US](https://longbridge.com/en/quote/ELTX.US.md)

## Related News & Research

- [Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering | ELTX Stock News](https://longbridge.com/en/news/291495074.md)
- [GT Biopharma Implements Reverse Stock Split, Streamlines Capital Structure](https://longbridge.com/en/news/297941721.md)
- [Alpha Compute to consolidate shares 1-for-50 in Nasdaq compliance bid](https://longbridge.com/en/news/297938537.md)
- [Apogee Therapeutics shares face Nasdaq suspension as company moves to delist after AbbVie merger](https://longbridge.com/en/news/297917721.md)
- [What is Zacks Research's Estimate for Exelixis Q4 Earnings?](https://longbridge.com/en/news/298028129.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**